Check for updates

OPEN ACCESS

EDITED BY Francesk Mulita, General University Hospital of Patras, Greece

REVIEWED BY Angelis Peteinaris, University of Patras, Greece Vasileios Tatanis, General University Hospital of Patras, Greece Georgios Tsakaldimis, Democritus University of Thrace, Greece Andreas Antzoulas, General University Hospital of Patras, Greece Dimitrios Diamantopoulos-Kogkas, General University Hospital of Patras, Greece

★CORRESPONDENCE Li Tong ♀ qhtongli@126.com

RECEIVED 23 April 2024 ACCEPTED 17 July 2024 PUBLISHED 31 July 2024

CITATION

Zeng X and Tong L (2024) Genetic and causal relationship between chronic gastrointestinal diseases and erectile dysfunction: a Mendelian randomization study. *Front. Med.* 11:1422267. doi: 10.3389/fmed.2024.1422267

COPYRIGHT

© 2024 Zeng and Tong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Genetic and causal relationship between chronic gastrointestinal diseases and erectile dysfunction: a Mendelian randomization study

Xiaoyan Zeng^{1,2,3} and Li Tong^{1,2*}

¹Qinghai University, Xining, China, ²Qinghai Provincial Key Laboratory of Traditional Chinese Medicine Research for Glucolipid Metabolic Diseases, Xining, China, ³The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi City, China

Background: Studies based on observations have indicated potential associations between chronic gastrointestinal diseases and an increased risk of erectile dysfunction (ED). However, the causality of these connections remains ambiguous.

Methods: Summary data for chronic gastrointestinal diseases were extracted from public data. Summary data on ED were extracted from three distinct sources. The genetic correlations between chronic gastrointestinal diseases and ED were explored using linkage disequilibrium score regression (LDSC). The causal associations between chronic gastrointestinal diseases and ED were evaluated using Mendelian randomization (MR) analysis, followed by a meta-analysis to determine the ultimate causal effect.

Results: The LDSC results suggested significant genetic correlations between Crohn's disease (CD) and ED. Inflammatory bowel disease (IBD), ulcerative colitis (UC), and liver cirrhosis (LC) were found to have potential genetic correlations with ED. The combined multiple MR results indicate that IBD and CD have significant causal relationships with ED, while colorectal cancer (CRC) may have a potential causal effect on ED.

Conclusion: This research provided evidence supporting a causal association between IBD, CD, CRC, and ED. The impact of chronic gastrointestinal diseases on ED warrants greater attention in clinical practice.

KEYWORDS

Mendelian randomization, chronic gastrointestinal diseases, erectile dysfunction, inflammatory bowel disease, colorectal cancer

1 Introduction

Erectile dysfunction (ED) is characterized by the inability to attain and sustain a satisfactory penile erection (1, 2). According to Goldstein et al.'s research, the prevalence of ED varied among nations, with rates ranging from 37.2% to 48.6%, while a recent study indicated that the prevalence of ED in younger males was approximately 30% (3, 4). ED shows a robust correlation with several chronic conditions, including chronic gastrointestinal diseases. An observation-based investigation emphasized a significant connection between chronic gastrointestinal diseases and ED, although the exact cause-and-effect relationship remains uncertain (5).

According to reports, chronic gastrointestinal diseases hurt male sexual function; however, the exact mechanism remains ambiguous (6). Chronic gastrointestinal diseases

may trigger inflammatory responses in the body, which can disrupt normal physiological processes and potentially lead to ED. Psychological stress arising from chronic gastrointestinal diseases might impact sexual function. Additionally, changes in endocrine levels, such as sex hormones, could result in genital dysfunction (5). Epidemiological research has found that chronic gastrointestinal diseases may increase the incidence of ED. Nevertheless, the current research displays inadequacies that hinder the formation of convincing evidence for these associations. Clarifying the causal links between chronic gastrointestinal diseases and ED is vital for developing targeted prevention strategies and improving patient outcomes. Unmeasurable confounders, like diabetes, and reverse causation make these causal associations difficult to clarify (7). Mendelian randomization (MR) has emerged as a dependable tool in epidemiological research for determining causality (8).

The use of MR in epidemiological research is an emerging methodology, using genetic variants as instrumental variables (IVs) to establish causal associations between exposures and outcomes (9, 10). Compared with observational studies, MR is adept at alleviating the impact of confounders and reverse causation (11). In addition, MR can effectively save financial and human resource costs (12). Several genome-wide association studies (GWAS) provide dependable IVs in MR studies by using genetic variations. To mitigate the influence of environmental factors, alleles adhere to the principle of independent assortment, resembling the structure of randomized controlled trials (RCTs) (13, 14).

Thus, a two-sample MR analysis was conducted to comprehensively investigate the causality of chronic gastrointestinal diseases [chronic gastritis (CG), peptic ulcer disease (PUD), gastric cancer (GC), inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC), celiac disease (CeD), irritable bowel syndrome (IBS), nonalcoholic fatty liver disease (NAFLD), colorectal cancer (CRC), alcoholic liver disease (ALD), chronic pancreatitis (CP), liver cirrhosis (LC)] on ED.

2 Materials and methods

2.1 Research design

Initially, we calculated the genetic correlations between chronic gastrointestinal diseases and ED. Subsequently, the causal relationships between chronic gastrointestinal diseases and ED were explored using MR analysis, by analyzing data from the FinnGen study (Figure 1). Then, we performed replication studies using the UK Biobank data on ED and additional GWAS summary data (Figure 1). Ultimately, we integrated the results from these MR studies (Figure 1). The single nucleotide polymorphism (SNP) used in our research must adhere to three key assumptions: 1. Close connection of the exposure to the IV is essential. 2. The outcome is directly influenced by the IV primarily through exposure. 3. The IV should demonstrate no correlation with potential confounding factors (15, 16). Our GWAS data summaries sourced from published GWAS research, did not require ethics committee approval.

2.2 GWAS summary data sources

The IEU OpenGWAS project has provided summary data for CG, GC, LC, and CP (17), including 3,645 CG patients (441,451 controls), 1029 GC patients (475,087 controls), 122 LC patients (347,284 controls), and 1,424 CP patients (476,104 controls). The summary statistical data of PUD was sourced from a genome-wide association study (920 cases, 55,717 controls) (17, 18). The International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) provided IBD, UC, and CD GWAS data. The data included 21,770 controls and 12,882 IBD cases, 14,927 controls, and 5,956 CD cases, as well as 33,977 controls and 13,768 UC cases (19). Summary data from a published GWAS study yielded 12,041 cases and 12,228 controls for Ced (20). Another GWAS study by Eijsbouts C et al. contributed summary data for IBS, comprising 53,400 cases and 433,201 controls (21). Additionally, a GWAS analysis on CRC (11,835 patients, 11,856 controls) offered data for CRC (22). The NAFLD summary data was from a GWAS analysis (8,434 cases, 770,180 controls) (23). The summary data for ALD (451 cases and 455,897 controls) was derived from analyses of UK Biobank data by Jiang et al. (24).

In the discovery stage, we chose the FinnGen consortium's data on ED, comprising 1,154 cases and 94,024 controls. For replication stage 1, the study used summary data for ED in the UK Biobank study (357 patients and 208,451 controls) (24). Additionally, data from a GWAS study on ED, with 6,175 cases and 217,360 controls, was selected for replication stage 2 (25). ED was defined as self-reported or physician-reported ED using ICD10 codes N48.4 and F52.2, or use of oral ED medication, or a history of surgical intervention for ED (using OPCS-4 codes L97.1 and N32.6). All participants were reported to have European ancestry. Supplementary Table 1 contains details of the data sources.

2.3 Genetic instruments selection

To ensure high-quality SNPs, we followed rigorous procedures. SNPs associated with IBD, CD, CeD, and UC were identified at $P < 5 \times 10^{-8}$. SNPs demonstrating a strong association with CP were selected at $P < 5 \times 10^{-6}$ (26). $P < 1 \times 10^{-5}$ was employed for CG, PUD, GC, IBS, CRC, NAFLD, LC, and ALD (27). To prevent linkage disequilibrium, a stringent criterion was implemented, setting kb at 10,000 and requiring r^2 to be <0.001 (28). During the harmonization process, palindromic and incompatible alleles were systematically excluded. To prevent potential pleiotropic effects, SNPs associated with confounding factors like diabetes and hypertension were removed using PhenoScanner V2 (29). Moreover, to minimize weak instrumental variable bias, we specifically chose SNPs with *F* statistic >10 ($F = Beta^2/SE^2$)



for MR study (30). Supplementary Tables 2-4 contain details of the SNPs.

2.4 Statistical analysis

The genetic correlations between chronic gastrointestinal diseases and ED were assessed using linkage disequilibrium score regression (LDSC). LDSC calculated genetic correlation using GWAS data, unaffected by sample overlap (31, 32). The correlation is represented as genetic covariance normalized by SNP heritability (33). Causal associations between chronic gastrointestinal diseases and ED were primarily evaluated by the inverse variance weighted (IVW) method (9, 34). The sensitivity analyses included weighted median (WM), MR-Egger, weighted mode, and simple mode. Reliable causal estimates can be provided by the WM method when over half of the weight stems from valid IVs (35). Despite the presence of pleiotropy in the IVs, the MR-Egger approach can still produce reliable estimates (36). The weighted model is considered valid for conducting causal inference in the MR study (37). A less powerful alternative, the simple mode method, was also employed in our study (38). Heterogeneity among SNPs was assessed through Cochrane's Q test, whereas horizontal pleiotropy was examined by analyzing the intercept in MR-Egger analysis (39). We used MR-PRESSO analysis to help identify potential outliers that could impact the results and then refine the causal estimates by excluding these outlying instrumental variables (36). The SNPs showed no significant heterogeneity or pleiotropy if the P values were above 0.05. A leave-one-out analysis was conducted to enhance the accuracy of causal estimates (40). Finally, we used the meta-analysis to explore the final causality, by integrating the initial discovery phase and the subsequent replication stage results (41). A fixed-effects model was chosen for I² values \leq 50%, while a random-effects model was used for I^2 values >50%.

In this study, a rigorous Bonferroni correction was implemented. P < 0.0038 (0.05/13) indicated significant

causal relationships between chronic gastrointestinal diseases and ED. *P* values ranging from 0.0038 to 0.05 suggested possible causation. The statistical analysis was conducted with the TwoSampleMR and MR-PRESSO (36, 40) packages in R version 4.3.2.

3 Results

3.1 Genetic correlation

LDSC regression analysis was conducted using FinnGen data. Due to the limitation of low heritability, ALD was not included in the above analysis. We observed a significant forward genetic correlation between CD and ED (r_g = 0.420, p = 0.003) (Figure 2). IBD (r_g = 0.420, p=0.008) and UC (r_g = 0.489, p = 0.008) exhibited potential forward genetic correlations with ED (Figure 2). Furthermore, a negative suggestive genetic correlation was identified between LC and ED (r_g = -1.209, p = 0.015) (Figure 2).

3.2 Discovery results

In the discovery stage, it was observed that IBD (OR = 1.110, 95% CI = 1.017-1.211, P = 0.019), CD (OR = 1.114, 95% CI = 1.034-1.201, P = 0.005), and CRC (OR = 1.216, 95% CI = 1.062-1.393, P = 0.005) may have potential associations with ED (Figure 3). Significant heterogeneity was not observed in the Cochran's Q test in this study (Table 1). The MR-Egger intercept test and MR-PRESSO global tests revealed no evidence of pleiotropy (Table 1). Furthermore, there were no outliers found, and the robustness of the findings was additionally confirmed through the leave-one-out examination.



3.3 Replication results

In the initial stage of validation, our analysis focused on ED data obtained from the UK Biobank study. Our IVW analysis revealed that IBD (OR = 1.279, 95% CI = 1.024–1.579, P = 0.030) and LC (OR = 0.849, 95% CI = 0.730–0.987, P = 0.034) may increase the risk of ED (Figure 4). There were no significant findings of pleiotropy or heterogeneity (Table 1). Through leave-one-out analysis, no single SNP significantly influenced the estimated correlation was found. Additionally, the replication study in stage 2 did not find any gastrointestinal disorders that had an impact on erectile dysfunction (Supplementary Table 5).

3.4 Final causality of chronic gastrointestinal diseases on ED

Our meta-analysis synthesized a minimum of two trustworthy MR analysis studies. However, only one reliable MR analysis result was available for the relationship between ALD and ED, thus the final determination of causality between ALD and ED was based on this single result. The results revealed a significant causality between IBD and ED (OR = 1.131, 95% CI = 1.043–1.226, P = 0.003), as well as a significant causal association between CD and ED (OR = 1.112, 95% CI = 1.037–1.193, P = 0.003) (Figure 5). Moreover, the pooled analysis indicated that CRC had a potential causal effect on ED (OR = 1.214, 95% CI = 1.065–1.385, P = 0.004) (Figure 5). Notably, our analysis did not find causality between other chronic gastrointestinal diseases and ED based on the combined results.

4 Discussion

The incidence of ED is associated with various risk factors, such as socioeconomic status, mental health issues, and physical

health conditions (42). However, the relationships between chronic gastrointestinal disease and sexual function have been neglected.

The causal relationships between chronic gastrointestinal disease and ED were thoroughly explored in our recent study using MR analysis. The results of LDSC regression analysis indicated a significant forward genetic correlation between CD and ED. Potential forward genetic correlations were identified between IBD and UC with ED, whereas LC showed a negative suggestive genetic correlation with ED. The MR study revealed robust associations between IBD and CD with ED. Additionally, our findings suggested a possible causal relationship between CRC and ED. Overall, the study illuminates the potential influence of gastrointestinal health on erectile function.

Previous observational studies have faced challenges in establishing causal conclusions between IBD and ED (43). Confounding factors could potentially influence the results, and the possibility of reverse causation adds further complexity to determining causality. A prospective cohort study demonstrated that a significant proportion of male IBD patients reported suffering from ED (44). Another systematic review estimated the prevalence of ED in approximately 27% of all patients with IBD (45). Furthermore, a cross-sectional study emphasized an increased risk of ED associated with IBD, underscoring the importance of addressing sexual health issues in this specific patient cohort (46). Conversely, another cross-sectional study involving 119 male patients with IBD found no significant association between IBD and ED (47). In conventional observational studies, the presence of numerous confounding factors may account for the disparate results. The MR analysis we used can effectively mitigate biases related to confounders like hypertension and diabetes, as well as biases related to reverse causality concerns (48). The combined findings of our study revealed a strong association between IBD and ED. Additionally, the evidence derived from the study suggested that CD presented a significant risk for developing ED. Our MR study is consistent with a recent study. Our investigation has the advantage of examining the relationship between IBD and ED by analyzing data from two large databases-the FinnGen

20	MB Eggor	20		
JG		29		1.06(0.89 to 1.27) 0.502
	vveighted median	29	Here a	1.01(0.88 to 1.16) 0.900
	Inverse variance weighted	29	191	0.98(0.89 to 1.07) 0.624
	Simple mode	29	H-81	0.94(0.76 to 1.15) 0.543
	Weighted mode	29		1.01(0.86 to 1.18) 0.909
PUD	MR Egger	15		1.14(0.93 to 1.39) 0.243
	Weighted median	15	HE-1	1.05(0.95 to 1.16) 0.330
	Inverse variance weighted	15	1941 1	1.05(0.98 to 1.13) 0.157
	Simple mode	15	He-1	1.06(0.95 to 1.20) 0.314
	Weighted mode	15	He-I	1.07(0.97 to 1.19) 0.217
GC	MR Egger	27	HO-1	1.01(0.90 to 1.13) 0.861
	Weighted median	27	HeH	0.94(0.83 to 1.06) 0.328
	Inverse variance weighted	27	101	0.95(0.87 to 1.04) 0.318
	Simple mode	27		0.93(0.77 to 1.12) 0.426
	Weighted mode	27	ren	0.94(0.84 to 1.05) 0.318
BD	MR Egger	121	IBI	1.34(1.08 to 1.66) 0.008
	Weighted median	121	I-8-1	1.19(1.05 to 1.35) 0.006
	Inverse variance weighted	121		1.11(1.02 to 1.21) 0.019
	Simple mode	121	r <mark>¦ ●</mark> → 1	1.27(0.93 to 1.73) 0.137
	Weighted mode	121	1 1	1.33(1.05 to 1.69) 0.019
JC	MR Egger	75		1.11(0.88 to 1.41) 0.381
	Weighted median	75	+++-	0.99(0.86 to 1.14) 0.899
	Inverse variance weighted	75	194	1.04(0.94 to 1.14) 0.440
	Simple mode	75		0.89(0.64 to 1.24) 0.506
	Weighted mode	75		0.85(0.61 to 1.18) 0.326
CD	MR Egger	39		1.11(0.93 to 1.33) 0.257
	Weighted median	39	1-0-1	1.19(1.06 to 1.33) 0.002
	Inverse variance weighted	39	101	1.11(1.03 to 1.20) 0.005
	Simple mode	39	H	1.20(0.95 to 1.51) 0.124
	Weighted mode	39		1.21(1.02 to 1.43) 0.039
CeD	MR Egger	11		1 01(0 83 to 1 22) 0 947
	Weighted median	11	Hard States	1.03(0.90 to 1.18) 0.663
	Inverse variance weighted	11		1 11(0 97 to 1 27) 0 134
	Simple mode	11		1.63(1.12 to 2.39) 0.030
	Weighted mode	11		1.03(1.12 to 2.03) 0.000
RS	MR Egger	68		1.01(0.53 to 1.15) 0.890
63	Weighted median	69		1.11(0.72 to 1.73) 0.683
	veighted median	00		1.11(0.72 (0 1.73) 0.632
	Simple mede	60		1.13(0.84 to 1.53) 0.411
	Simple mode	66		
200	vveighted mode	68		0.96(0.42 to 2.19) 0.929
JRC		35		1.23(0.87 to 1.73) 0.259
	Weighted median	35		1.15(0.93 to 1.42) 0.190
	inverse variance weighted	35		1.22(1.06 to 1.39) 0.005
	Simple mode	35		1.14(0.79 to 1.66) 0.487
	vveighted mode	35		1.18(0.89 to 1.55) 0.263
NAFLD	MR Egger	15		0.57(0.21 to 1.56) 0.293
	Weighted median	15		0.68(0.45 to 1.03) 0.070
	Inverse variance weighted	15		0.82(0.60 to 1.13) 0.229
	Simple mode	15		0.60(0.31 to 1.16) 0.149
	Weighted mode	15		0.61(0.33 to 1.14) 0.143
ALD	MR Egger	7	Heli	0.92(0.80 to 1.06) 0.319
	Weighted median	7		1.01(0.92 to 1.12) 0.769
	Inverse variance weighted	7	6 1 0-1	1.05(0.95 to 1.15) 0.317
	Simple mode	7	ret-r	1.00(0.90 to 1.13) 0.944
	Weighted mode	7	101	1.00(0.91 to 1.11) 0.936
_C	MR Egger	24		1.00(0.96 to 1.05) 0.876
	Weighted median	24		0.99(0.95 to 1.03) 0.540
	Inverse variance weighted	24		0.99(0.94 to 1.04) 0.597
	Simple mode	24	101	1.02(0.96 to 1.08) 0.589
	Weighted mode	24	÷	0.99(0.94 to 1.04) 0.785
CP	MR Egger	16	t-Brit	0.93(0.82 to 1.06) 0.266
	Weighted median	16		1.04(0.83 to 1.30) 0.742
	Inverse variance weighted	16	H-4-1	0.98(0.83 to 1.16) 0.828
	Simple mode	16		1.04(0.78 to 1.38) 0.803
				·····, ·····
	Weighted mode	16		1.02(0.79 to 1.33) 0.867

FIGURE 3

Causal estimates of chronic gastrointestinal diseases on ED in FinnGen. CI, confidence interval; CG, chronic gastritis; PUD, peptic ulcer disease; GC, gastric cancer; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn's disease; CeD, celiac disease; IBS, irritable bowel syndrome; CRC, colorectal cancer; NAFLD, nonalcoholic fatty liver disease; ALD, alcoholic liver disease; LC, liver cirrhosis; CP, chronic pancreatitis.

TABLE 1 Heterogeneity and pleiotropy test.

Exposure	Data sources	Cochran's Q MR Egger		ger	MR PRESSO		
		Q	Р	Intercept	Р	Global test RSSobs	Р
CG	FinnGen	22.590	0.753	-0.023	0.267	24.413	0.760
	UK Biobank	4.166	0.842	-0.002	0.972	5.402	0.854
	Bovijn J et al.	37.292	0.113	-0.010	0.376	40.141	0.105
PUD	FinnGen	10.034	0.760	-0.039	0.453	11.290	0.792
	UK Biobank	5.802	0.326	0.194	0.258	7.332	0.430
	Bovijn J et al.	11.240	0.591	0.006	0.802	12.827	0.647
GC	FinnGen	21.319	0.725	-0.027	0.125	22.349	0.759
	UK Biobank	12.046	0.524	0.038	0.443	13.455	0.567
	Bovijn J et al.	16.359	0.979	0.003	0.757	17.369	0.978
IBD	FinnGen	138.330	0.121	-0.022	0.058	140.883	0.118
	UK Biobank	35.717	0.777	0.008	0.751	37.038	0.789
UC	FinnGen	80.056	0.295	-0.009	0.533	82.836	0.278
	UK Biobank	13.437	0.991	0.013	0.715	15.002	0.985
CD	FinnGen	32.804	0.708	0.000	0.984	34.844	0.694
	UK Biobank	8.998	0.773	-0.002	0.965	9.900	0.807
CeD	FinnGen	17.241	0.069	0.041	0.202	21.513	0.101
	UK Biobank	3.234	0.779	-0.088	0.145	3.716	0.848
	Bovijn J et al.	4.169	0.842	0.005	0.755	4.914	0.860
IBS	FinnGen	69.555	0.392	0.003	0.880	71.601	0.379
	UK Biobank	32.752	0.288	0.010	0.865	35.003	0.292
CRC	FinnGen	34.856	0.427	-0.001	0.965	36.786	0.450
	UK Biobank	3.733	0.880	0.118	0.211	4.599	0.893
NAFLD	FinnGen	16.801	0.267	0.041	0.459	19.256	0.267
	UK Biobank	6.666	0.353	0.059	0.834	9.050	0.390
ALD	FinnGen	10.072	0.122	0.100	0.095	12.691	0.183
LC	FinnGen	16.667	0.825	-0.018	0.187	0.292	0.852
	UK Biobank	4.096	0.536	0.012	0.809	4.554	0.726
	Bovijn J et al.	28.230	0.297	-0.006	0.510	30.553	0.307
СР	FinnGen	6.384	0.973	-0.042	0.263	7.288	0.976
	UK Biobank	1.463	0.691	-0.044	0.728	2.412	0.707
	Bovijn J et al.	12.890	0.535	-0.010	0.565	15.209	0.481

and the UK Biobank study. By combining the findings from both datasets through meta-analysis, we were able to provide a more comprehensive conclusion. This methodology enhanced the reliability of our MR findings. In our MR analysis, CD was recognized as a contributing factor to ED, whereas UC did not exhibit any correlation with ED. This discrepancy may be attributed to genetic variations between CD and UC. Further research is required to validate this hypothesis (14). A potential mechanism underlying the association between IBD and ED involves hypogonadism and microvascular endothelial dysfunction as a result of chronic inflammation (46, 49). Previous prospective cohort studies have suggested an association between CRC and ED, although this connection remains inconclusively verified (50). Our study discovered a possible connection between CRC and ED by analyzing ED data from the FinnGen database. This correlation was confirmed through a comprehensive meta-analysis. Additionally, our research did not reveal any significant indications of pleiotropy or heterogeneity, indicating a robust and reliable association between CRC and ED. Pelvic pain, nerve damage, and fibrosis of the genital tissues induced by CRC could represent potential mechanisms underlying this correlation (51).

Exposure	Method	nSNP		OR(95%CI)	P.value
CG	MR Egger	9	· · · · · · · · · · · · · · · · · · ·	1.12(0.66 to 1.92)	0.684
	Weighted median	9		1.01(0.67 to 1.53)	0.956
	Inverse variance weighted	9		1.11(0.82 to 1.51)	0.493
	Simple mode	9		1.00(0.53 to 1.87)	0.991
	Weighted mode	9		0.97(0.62 to 1.51)	0.902
PUD	MR Egger	6		0.80(0.51 to 1.27)	0.399
	Weighted median	6		1.05(0.83 to 1.33)	0.660
	Inverse variance weighted	6		1.07(0.88 to 1.28)	0.500
	Simple mode	6		1 07(0 76 to 1 53)	0 704
	Weighted mode	6		1.05(0.82 to 1.35)	0.729
GC	MR Egger	14		0.98(0.72 to 1.34)	0.903
00		14		1.02(0.76 to 1.37)	0.000
	Inverse variance weighted	14		1.02(0.70 to 1.37)	0.512
	Simple mode	14		1.18(0.78 to 1.78)	0.000
		14		1.16(0.78 to 1.78)	0.451
00	vveighted mode	14		1.01(0.72 to 1.42)	0.951
вD		44		1.20(0.78 to 1.86)	0.415
	vveighted median	44		1.26(0.89 to 1.78)	0.185
	inverse variance weighted	44		1.28(1.02 to 1.60)	0.030
	Simple mode	44		1.28(0.74 to 2.22)	0.383
	Weighted mode	44	1	1.23(0.86 to 1.77)	0.259
UC	MR Egger	29		1.10(0.65 to 1.87)	0.726
	Weighted median	29		1.33(0.94 to 1.89)	0.113
	Inverse variance weighted	29		1.20(0.94 to 1.53)	0.136
	Simple mode	29		1.39(0.74 to 2.59)	0.314
	Weighted mode	29	+ --- +	1.34(0.84 to 2.14)	0.224
CD	MR Egger	14	t − 1 ⊕−−−1	1.10(0.79 to 1.54)	0.582
	Weighted median	14	i <mark>¦e</mark> ⊶i	1.14(0.88 to 1.47)	0.314
	Inverse variance weighted	14	r <mark>¦</mark> e⊶(1.09(0.90 to 1.33)	0.355
	Simple mode	14		1.11(0.75 to 1.65)	0.613
	Weighted mode	14		1.13(0.87 to 1.47)	0.374
CeD	MR Egger	7	101	0.89(0.76 to 1.05)	0.179
	Weighted median	7		1.05(0.82 to 1.34)	0.736
	Inverse variance weighted	7	1-0-1	0.92(0.76 to 1.12)	0.417
	Simple mode	7		0.90(0.68 to 1.18)	0.468
	Weighted mode	7	l Hel-l	0.92(0.77 to 1.10)	0.400
BS	MR Egger	30		→ 1 11(0 07 to 17 82)	0.940
20	Weighted median	30		1 75(0 58 to 5 31)	0.320
	Inverse variance weighted	30		1 40(0 59 to 3 33)	0.020
	Simple mode	20		1.40(0.39 to 3.33)	0.602
	Simple mode	30		1.83(0.19 to 17.46)	0.603
	MB Egger	30			0.395
GRU		9			0.387
	vveignted median	9		0.97(0.49 to 1.94)	0.934
	inverse variance weighted	9		1.18(0.70 to 2.01)	0.536
	Simple mode	9		1.10(0.42 to 2.84)	0.849
	Vveighted mode	9		1.07(0.41 to 2.83)	0.890
NAFLD	MR Egger	7	•	> 0.68(0.00 to 189.33)	0.897
	Weighted median	7	•	► 1.73(0.57 to 5.26)	0.333
	Inverse variance weighted	7		1.27(0.56 to 2.85)	0.567
	Simple mode	7	-	► 2.78(0.49 to 15.60)	0.290
	Weighted mode	7		> 2.70(0.48 to 15.09)	0.300
LC	MR Egger	6	10-1	0.84(0.70 to 1.00)	0.125
	Weighted median	6	H B-1	0.84(0.70 to 1.02)	0.079
	Inverse variance weighted	6	101	0.85(0.73 to 0.99)	0.034
	Simple mode	6		0.81(0.62 to 1.06)	0.186
	Weighted mode	6	10-1	0.84(0.71 to 1.01)	0.120
CP	MR Egger	4	L	1.35(0.70 to 2.59)	0.464
	Weighted median	4		1.16(0.74 to 1.80)	0.524
	Inverse variance weighted	4		1.21(0.84 to 1.74)	0.309
	Cimple mode	4		1 02(0 57 to 1 83)	0.954
	Simple mode				

FIGURE 4

Causal estimates of chronic gastrointestinal diseases on ED in UK Biobank. CI, confidence interval; CG, chronic gastritis; PUD, peptic ulcer disease; GC, gastric cancer; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn's disease; CeD, celiac disease; IBS, irritable bowel syndrome; CRC, colorectal cancer; NAFLD, nonalcoholic fatty liver disease; LC, liver cirrhosis; CP, chronic pancreatitis.

Exposure	Datasources	or			OR(95%CI)	P.value
CG	FinnGen+UK Biobank+Bovijn J et al	GWAS 0.978	Held		0.98(0.93 to 1.03)	0.390
PUD	FinnGen+UK Biobank+Bovijn J et al	GWAS 1.011	HHH		1.01(0.95 to 1.08)	0.741
GC	FinnGen+UK Biobank+Bovijn J et al	GWAS 1.019	HHH		1.02(0.98 to 1.06)	0.399
IBD	FinnGen+UK Biobank	1.131	H-81		1.13(1.04 to 1.23)	0.003
UC	FinnGen+UK Biobank	1.059			1.06(0.97 to 1.16)	0.207
CD	FinnGen+UK Biobank	1.112			1.11(1.04 to 1.19)	0.003
CeD	FinnGen+UK Biobank+Bovijn J et al	GWAS 0.994	—		0.99(0.89 to 1.11)	0.909
IBS	FinnGen+UK Biobank	1.159			1.16(0.87 to 1.54)	0.305
CRC	FinnGen+UK Biobank	1.214			1.21(1.06 to 1.38)	0.004
NAFLD	FinnGen+UK Biobank	0.872	⊢		0.87(0.65 to 1.17)	0.359
ALD	FinnGen	1.049	HT BI		1.05(0.95 to 1.15)	0.317
LC	FinnGen+UK Biobank+Bovijn J et al	GWAS 0.998	+		1.00(0.98 to 1.02)	0.867
CP	FinnGen+UK Biobank+Bovijn J et al	GWAS 1.013	HH-		1.01(0.96 to 1.06)	0.622
		0 5	1	15	2	
FIGURE 5					-	

Final causality of chronic gastrointestinal diseases on ED. CI, confidence interval; CG, chronic gastritis; PUD, peptic ulcer disease; GC, gastric cancer; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn's disease; CeD, celiac disease; IBS, irritable bowel syndrome; CRC, colorectal cancer; NAFLD, nonalcoholic fatty liver disease; ALD, alcoholic liver disease; LC, liver cirrhosis; CP, chronic pancreatitis.

Associations between LC and ED were observed in the UK Biobank, but not found in the FinnGen and Bovijn J et al.' GWAS. This discrepancy could be due to differences in gene pool composition between the three databases (52). The observed discrepancy may also be influenced by the insufficient statistical power in the replication stage 1, as the sample size of ED cases in UKB was much smaller than in FinnGen and Bovijn J et al.' GWAS. Additionally, our method of selecting IVs may not entirely eliminate weak instrumental bias, which could also impact the differences in results. However, the combined result confirmed no causal relationship between LC and ED, indicating the reliability of the result.

A prior observational study indicated a relationship between ALD and ED (53). However, our MR research did not reveal a direct causal connection between ALD and ED. This evaluation of causality was exclusively carried out in the FinnGen database due to restricted GWAS data availability. Further investigation is necessary to provide a more in-depth comprehension of the potential relationship between ALD and ED.

Previous observational studies have suggested relationships between CG, PUD, GC, CeD, IBS, NAFLD, CP, and ED. However, these connections were not supported by the findings of this study. Causal relationships between CG, PUD, GC, CeD, IBS, NAFLD, CP, and ED cannot be definitively excluded in our MR study due to limited evidence.

Our MR research provides significant advantages. This study stands out as the first comprehensive investigation in this area, distinguishing it from previous observational studies. By using MR analysis, we were able to address potential biases, enhancing the credibility of our findings. Moreover, our selection of GWAS data primarily from European populations helped to minimize population structure bias. In addition, we undertook an additional measure by performing a Meta-analysis on three sources of GWAS data to strengthen the reliability of research findings. Furthermore, sensitivity analyses were applied to address issues such as horizontal pleiotropy and potential statistical biases.

However, acknowledging the limitations of our research is crucial. Firstly, the use of data from various sources to enhance result confidence might have introduced heterogeneity in the meta-analysis, attributable to the differing definitions of ED cases among various databases. Secondly, although MR analyses typically require non-overlapping participants between exposure and outcome samples, we were unable to determine if there was any sample overlap in our study. Nonetheless, we minimized potential bias from sample overlap by excluding IVs with F statistics < 10. Thirdly, insufficient suitable data prevented us from conducting sex-stratified analyses and assessing the severity and type of ED, potentially introducing biases. Additionally, as the SNPs examined were only of European descent, we cannot apply our findings to other populations. As indicated by the European Association of Urology (EAU) Guidelines for Male Ailments, the incidence of ED is steadily on the rise across all racial groups (54). Hence, further investigation is warranted to explore the causal link between chronic gastrointestinal disorders and ED across various racial demographics. Moreover, even though we made an effort to account for gene pleiotropy in our analysis, biases may still be present. Consequently, future research endeavors must include larger sample sizes in MR studies or RCTs to confirm the results of our study.

In conclusion, a causal relationship exists between IBD, CD, CRC, and ED. IBD, CD, and CRC may elevate the likelihood of developing ED.

5 Conclusion

In summary, IBD and UC show potential forward genetic correlations with ED, while CD has a significant forward genetic correlation with ED. Additionally, LC demonstrates a suggestive

negative genetic correlation with ED. MR analysis indicates significant causal relationships between IBD and CD with ED, while CRC may have a potential causal effect on ED. These results underscore the importance of considering the impact of chronic gastrointestinal diseases on ED in clinical practice.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary material.

Author contributions

XZ: Writing – original draft, Software, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. LT: Writing – review & editing, Supervision.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the "Kunlun Talents, High-end Innovation and Entrepreneurial Talents" Leading Talents Project.

References

1. Kim SG, You D, Kim K, Aum J, Kim YS, Jang MJ, et al. Therapeutic effect of human mesenchymal stem cell-conditioned medium on erectile dysfunction. *World J Mens Health*. (2022) 40:653–62. doi: 10.5534/wjmh.210121

2. Banks E, Joshy G, Abhayaratna WP, Kritharides L, Macdonald PS, Korda RJ, et al. Erectile dysfunction severity as a risk marker for cardiovascular disease hospitalisation and all-cause mortality: a prospective cohort study. *PLoS Med.* (2013) 10:e1001372. doi: 10.1371/journal.pmed.1001372

3. Goldstein I, Goren A, Li VW, Tang WY, Hassan TA. Epidemiology update of erectile dysfunction in eight countries with high burden. *Sex Med Rev.* (2020) 8:48–58. doi: 10.1016/j.sxmr.2019.06.008

4. Yin T, Liu Q, Ma Z, Li Z, Sun R, Ren F, et al. Associations between altered cerebral activity patterns and psychosocial disorders in patients with psychogenic erectile dysfunction: a mediation analysis of fMRI. *Front Psychiatry*. (2020) 11:583619. doi: 10.3389/fpsyt.2020.583619

5. Romano L, Granata L, Fusco F, Napolitano L, Cerbone R, Priadko K, et al. Sexual dysfunction in patients with chronic gastrointestinal and liver diseases: a neglected issue. *Sex Med Rev.* (2022) 10:620–31. doi: 10.1016/j.sxmr.2021. 02.002

6. Bouchoucha M, Devroede G, Mary F, Bon C, Bejou B, Benamouzig R. Both men and women with functional gastrointestinal disorders suffer from a high incidence of sexual dysfunction. *Clin Res Hepatol Gastroenterol.* (2017) 41:e93–e6. doi: 10.1016/j.clinre.2017.05.001

7. Trajanoska K, Rivadeneira F. Using Mendelian randomization to decipher mechanisms of bone disease. *Curr Osteoporos Rep.* (2018) 16:531–40. doi: 10.1007/s11914-018-0467-3

8. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. *BMJ*. (2021) 375:n2233. doi: 10.1136/bmj. n2233

9. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol.* (2013) 37:658–65. doi: 10.1002/gepi.21758

Acknowledgments

We would like to express our gratitude to the participants and investigators of the database used in this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2024. 1422267/full#supplementary-material

10. Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, et al. Recent developments in mendelian randomization studies. *Curr Epidemiol Rep.* (2017) 4:330–45. doi: 10.1007/s40471-017-0128-6

11. Pingault JB, O'Reilly PF, Schoeler T, Ploubidis GB, Rijsdijk F, Dudbridge F. Using genetic data to strengthen causal inference in observational research. *Nat Rev Genet.* (2018) 19:566–80. doi: 10.1038/s41576-018-0020-3

12. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *Bmj.* (2018) 362:k601. doi: 10.1136/bmj.k601

13. Evans DM, Davey Smith G. Mendelian randomization: new applications in the coming age of hypothesis-free causality. *Annu Rev Genomics Hum Genet.* (2015) 16:327–50. doi: 10.1146/annurev-genom-090314-050016

14. Chen D, Zhou C, Luo Q, Chen C, Liu G. A Mendelian randomization study on causal effects of inflammatory bowel disease on the risk of erectile dysfunction. *Sci Rep.* (2024) 14:2137. doi: 10.1038/s41598-024-52712-1

15. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. *Am J Clin Nutr.* (2016) 103:965–78. doi: 10.3945/ajcn.115.118216

16. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. *Jama.* (2021) 326:1614–21. doi: 10.1001/jama.2021.18236

17. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, et al. A crosspopulation atlas of genetic associations for 220 human phenotypes. *Nat Genet.* (2021) 53:1415–24. doi: 10.1038/s41588-021-00931-x

18. Guindo-Martínez M, Amela R, Bonàs-Guarch S, Puiggròs M, Salvoro C, Miguel-Escalada I, et al. The impact of non-additive genetic associations on age-related complex diseases. *Nat Commun.* (2021) 12:2436. doi: 10.1038/s41467-021-21952-4

19. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet.* (2015) 47:979–86.

20. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. *Nat Genet.* (2011) 43:1193–201. doi: 10.1038/ng.998

21. Eijsbouts C, Zheng T, Kennedy NA, Bonfiglio F, Anderson CA, Moutsianas L, et al. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. *Nat Genet.* (2021) 53:1543–52. doi: 10.1038/s41588-021-00950-8

22. Huyghe JR, Bien SA, Harrison TA, Kang HM, Chen S, Schmit SL, et al. Discovery of common and rare genetic risk variants for colorectal cancer. *Nat Genet.* (2019) 51:76–87. doi: 10.1038/s41588-018-0286-6

23. Ghodsian N, Abner E, Emdin CA, Gobeil É, Taba N, Haas ME, et al. Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. *Cell Rep Med.* (2021) 2:100437. doi: 10.1016/j.xcrm.2021.100437

24. Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for biobank-scale data. *Nat Genet.* (2021) 53:1616–21. doi: 10.1038/s41588-021-00954-4

25. Bovijn J, Jackson L, Censin J, Chen CY, Laisk T, Laber S, et al. GWAS identifies risk locus for erectile dysfunction and implicates hypothalamic neurobiology and diabetes in etiology. *Am J Hum Genet.* (2019) 104:157-63. doi: 10.1016/j.ajhg.2018.11.004

26. Kwok MK, Kawachi I, Rehkopf D, Schooling CM. The role of cortisol in ischemic heart disease, ischemic stroke, type 2 diabetes, and cardiovascular disease risk factors: a bi-directional Mendelian randomization study. *BMC Med.* (2020) 18:363. doi: 10.1186/s12916-020-01831-3

27. Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. *Nat Genet.* (2019) 51:600–5. doi: 10.1038/s41588-019-0350-x

28. Wu F, Huang Y, Hu J, Shao Z. Mendelian randomization study of inflammatory bowel disease and bone mineral density. *BMC Med.* (2020) 18:312. doi: 10.1186/s12916-020-01778-5

29. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics*. (2019) 35:4851–3. doi: 10.1093/bioinformatics/btz469

30. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. (2011) 40:755-64. doi: 10.1093/ije/dyr036

31. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, et al. An atlas of genetic correlations across human diseases and traits. *Nat Genet.* (2015) 47:1236–41. doi: 10.1038/ng.3406

32. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet.* (2015) 47:291–5. doi: 10.1038/ng.3211

33. Cui G, Li S, Ye H, Yang Y, Jia X, Lin M, et al. Gut microbiome and frailty: insight from genetic correlation and mendelian randomization. *Gut Microbes*. (2023) 15:2282795. doi: 10.1080/19490976.2023.2282795

34. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. *Wellcome Open Res.* (2019) 4:186. doi: 10.12688/wellcomeopenres.15555.1

35. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol.* (2016) 40:304–14. doi: 10.1002/gepi.21965

36. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet.* (2018) 50:693–8. doi: 10.1038/s41588-018-0099-7

37. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol.* (2017) 46:1985–98. doi: 10.1093/ije/dyx102

38. Li C, Niu M, Guo Z, Liu P, Zheng Y, Liu D, et al. A mild causal relationship between tea consumption and obesity in general population: a two-sample Mendelian randomization study. *Front Genet.* (2022) 13:795049. doi: 10.3389/fgene.2022.795049

39. Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. *Stat Med.* (2015) 34:2926–40. doi: 10.1002/sim.6522

40. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife.* (2018) 7:e34408. doi: 10.7554/eLife.34408

41. Freuer D, Meisinger C. Association between inflammatory bowel disease and Parkinson's disease: a Mendelian randomization study. *NPJ Parkinsons Dis.* (2022) 8:55. doi: 10.1038/s41531-022-00318-7

42. Kim H, Kim KT, Shin WC, Yang KI, Ha JY, Cho YW. Erectile dysfunction in patient with obstructive sleep apnea: effects of continuous positive airway pressure. *Aging Male.* (2024) 27:2317165. doi: 10.1080/13685538.2024.2317165

43. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature*. (2011) 474:307–17. doi: 10.1038/nature10209

44. Shmidt E, Suárez-Fariñas M, Mallette M, Moniz H, Bright R, Shah SA, et al. Erectile dysfunction is highly prevalent in men with newly diagnosed inflammatory bowel disease. *Inflamm Bowel Dis.* (2019) 25:1408–16. doi: 10.1093/ibd/izy401

45. Wu X, Zhang Y, Zhang W, Liu G, Huang H, Jiang H, et al. The prevalence and associated risk factors of erectile dysfunction in patients with inflammatory bowel disease: a systematic review and meta-analysis. *J Sex Med.* (2022) 19:950–60. doi: 10.1016/j.jscm.2022.03.615

46. Zhang J, Nie J, Zou M, Zeng Q, Feng Y, Luo Z, et al. Prevalence and associated factors of sexual dysfunction in patients with inflammatory bowel disease. *Front Endocrinol.* (2022) 13:881485. doi: 10.3389/fendo.2022.881485

47. Bel LG, Vollebregt AM, Van der Meulen-de Jong AE, Fidder HH, Ten Hove WR, Vliet-Vlieland CW, et al. Sexual dysfunctions in men and women with inflammatory bowel disease: the influence of IBD-related clinical factors and depression on sexual function. *J Sex Med.* (2015) 12:1557–67. doi: 10.1111/jsm.12913

48. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. *Stat Med.* (2016) 35:1880–906. doi: 10.1002/sim.6835

49. Hatoum OA, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. *Gastroenterology.* (2003) 125:58–69. doi: 10.1016/S0016-5085(03)00699-1

50. Sörensson M, Asplund D, Matthiessen P, Rosenberg J, Hallgren T, Rosander C, et al. Self-reported sexual dysfunction in patients with rectal cancer. *Colorectal Dis.* (2020) 22:500–12. doi: 10.1111/codi.14907

51. Rivière P, Zallot C, Desobry P, Sabaté JM, Vergniol J, Zerbib F, et al. Frequency of and factors associated with sexual dysfunction in patients with inflammatory bowel disease. *J Crohns Colitis.* (2017) 11:1347–52. doi: 10.1093/ecco-jcc/jjx100

52. Sun BB, Kurki MI, Foley CN, Mechakra A, Chen CY, Marshall E, et al. Genetic associations of protein-coding variants in human disease. *Nature*. (2022) 603:95–102. doi: 10.1038/s41586-022-04394-w

53. Bannister P, Oakes J, Sheridan P, Losowsky MS. Sex hormone changes in chronic liver disease: a matched study of alcoholic versus non-alcoholic liver disease. *Q J Med.* (1987) 63:305–13.

54. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. (2013) 381:153-65. doi: 10.1016/S0140-6736(12)60520-0